Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
US-9221788-B2 · Dec 29, 2015 · US
Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
US9757355B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9757355-B2 |
| Application number | US-201213978869-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 9, 2012 |
| Priority date | Jan 10, 2011 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. An oral dosage form consisting of about 9% by weight of a compound of formula (I): or a pharmaceutically acceptable salt thereof, about 34% by weight of mannitol, about 5% by weight of sodium croscarmellose, about 1% by weight of calcium stearate and about 51% by weight of polyvinylpyrrolidone-vinylacetate copolymer. 2. The oral dosage form of claim 1 , wherein the oral dosage form is prepared by the following process: (i) blend the compound of formula (I) with hydroxypropyl methylcellulose or polyvinylpyrrolidone-vinylacetate copolymer; (ii) process the blended product of (i) by hot melt extrusion at 190° C.; (iii) mill the extruded product of (ii) using 18 mesh screen; (iv) blend the milled extrudate of (iii) with prescreened crosscarmellose sodium and mannitol; (v) blend the product of (iv) with prescreened calcium stearate; and (vi) encapsulate the blended product of (v). 3. The oral dosage form of claim 2 , wherein the blending of steps (i) and (iv) is for 460 rotations each using a shaker mixer. 4. The oral dosage form of claim 2 , wherein the blending of step (v) is for 75 rotations using a shaker mixer. 5. The oral dosage form of claim 2 , wherein a semi-automatic encapsulator is used in step (vi).
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9757355B2 cover?
- Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.
- Who is the assignee on this patent?
- Chen Ming J, Hui Ho-Wah, Lee Thomas, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4035. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).